NCT06544083Recruiting
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood: a Multi-center, Prospective Study
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 16 Apr 2024
- Start date
- 5 Feb 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06544083
What you commit to
- Study type: Observational
- Planned participants: 600
- From 5 Feb 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous organ transplantation or non-autologous bone marrow or stem cell transplantation.
- Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc.
Other illness
- History of previous malignant tumors.
- Having other malignant tumors or multiple primary tumors at the same time.
Other
- Female subjects who are pregnant or breastfeeding.
Who the study is looking for
- Voluntarily sign informed consent.
- Male or female, age equal to or greater than 18 years and less than 75 years.
- Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection
- The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc.
- Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.